Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorraine A Fitzpatrick

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
The Journal of Clinical Endocrinology and Metabolism|March 2, 2013
Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitusJohn P Bilezikian, Robert G Josse, Richard Eastell, et al.
The Journal of Clinical Endocrinology and Metabolism|May 26, 2018
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal OsteoporosisHenry G Bone, Felicia Cosman, Paul D Miller, et al.
JAMA|August 18, 2016
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical TrialPaul D Miller, Gary Hattersley, Bente Juel Riis, et al.
Yonsei Medical Journal|May 19, 2016
Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label ExtensionJung Min Koh, Dong Jin Chung, Yoon Sok Chung, et al.
Yonsei Medical Journal|May 19, 2016
Vitamin D Repletion in Korean Postmenopausal Women with OsteoporosisYoon Sok Chung, Dong Jin Chung, Moo Il Kang, et al.
Indian Journal of Endocrinology and Metabolism|January 17, 2015
A randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal women with osteoporosisShailesh Pitale, Mathew Thomas, Gaurav Rathi, et al.
Bone|September 30, 2009
An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formationSanjay Kumar, Christopher J Matheny, Sandra J Hoffman, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
The Journal of Clinical Endocrinology and Metabolism|March 2, 2013
Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitusJohn P Bilezikian, Robert G Josse, Richard Eastell, et al.
The Journal of Clinical Endocrinology and Metabolism|May 26, 2018
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal OsteoporosisHenry G Bone, Felicia Cosman, Paul D Miller, et al.
JAMA|August 18, 2016
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical TrialPaul D Miller, Gary Hattersley, Bente Juel Riis, et al.
Yonsei Medical Journal|May 19, 2016
Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label ExtensionJung Min Koh, Dong Jin Chung, Yoon Sok Chung, et al.
Yonsei Medical Journal|May 19, 2016
Vitamin D Repletion in Korean Postmenopausal Women with OsteoporosisYoon Sok Chung, Dong Jin Chung, Moo Il Kang, et al.
Indian Journal of Endocrinology and Metabolism|January 17, 2015
A randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal women with osteoporosisShailesh Pitale, Mathew Thomas, Gaurav Rathi, et al.
Bone|September 30, 2009
An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formationSanjay Kumar, Christopher J Matheny, Sandra J Hoffman, et al.
Pageof 7